The Late Effects of Thorotrast Administration
Author Information
Author(s): J. P. Guimaraes, L. F. Lamerton, W. R. Christensen
Primary Institution: Royal Marsden Hospital
Hypothesis
Does intravenously administered thorotrast have carcinogenic effects?
Conclusion
The study found evidence of degenerative changes and tumors in mice after thorotrast administration, suggesting a potential causal relationship.
Supporting Evidence
- Five hepatomas were found in the liver of thorotrast-injected mice.
- One reticulo-endothelioma was observed in the liver.
- Seven lung tumors were identified in mice examined more than 15 months after injection.
- Control animals that lived over 12 months showed no tumors.
Takeaway
This study looked at how a substance called thorotrast might cause cancer in mice, and they found some signs that it could be harmful.
Methodology
The study involved injecting thorotrast into groups of mice and observing the effects over time, including histological examinations.
Limitations
The number of animals involved was small, and some records of deaths were incomplete.
Participant Demographics
Male Schofield albino mice, approximately 8 weeks old at the start of the experiment.
Want to read the original?
Access the complete publication on the publisher's website